Clinical trials: Movement Disorders
Parkinson Disease
Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
- Trial name
- NCT02970019
- Testing
- K0706
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Parkinson's Disease
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- NCT00455507
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 363 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson Disease
Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s Disease
This is an open-label, prospective post marketing surveillance study to be performed in Sweden. Only data of patients idiopathic PD should be documented, in whom the treating physician plans to initiate a pharmacotherapy with PPX…
- Trial name
- NCT01097421
- Testing
- Pramipexole Extended Release
- Volunteers
- 329 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations.
- Trial name
- NCT00936676
- Testing
- rasagiline mesylate
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 684 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
A Long-Term, Safety Study With a Flexible Dose Range of KW-6002 in Patients With Motor Response Complications on Levodopa/Carbidopa Therapy
The primary objective of this study was to establish the long-term tolerability and safety of istradefylline treatment in subjects with Parkinson's disease treated with levodopa/carbidopa.
- Trial name
- NCT00955045
- Testing
- istradefylline
- Where
- United States
- Sponsor
- Kyowa Kirin, Inc.
Parkinson Disease
OpicApone Sleep dISorder
The aim of this study is to To investigate in an exploratory manner the efficacy of 50 mg opicapone when administered with the existing treatment of levodopa (L-dopa) plus a dopa decarboxylase inhibitor (DDCI), in Parkinson's…
- Trial name
- OASIS (NCT04986995)
- Testing
- Opicapone
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Bial - Portela C S.A.
Dyskinesias
Open-Label Extension Study of ASTORIA
This current open-label extension (OLE) study (JM-010CS-OL) will explore the safety and tolerability of long-term administration of JM-010 of patients who completed 12-week treatment of Phase 2 (JM-010CS03) study.
- Trial name
- NCT05516875
- Testing
- JM-010
- Where
- 2 sites in Italy, Spain
- Volunteers
- 6 people
- Sponsor
- Contera Pharma A/S
Parkinson's Disease
Gastric Retentive Carbidopa/ Levodopa in Parkinson's Patients; a One Year, Open Label, Safety Extension Study
An extension of study IN 09 004 testing the long term safety of the Accordion Pill Carbidopa/Levodopa (AP-CD/LD)
- Trial name
- NCT00947037
- Testing
- AP-CD/LD
- Where
- 5 sites in Israel
- Sponsor
- Intec Pharma Ltd.
Tourette Syndrome
A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)
Standard placebo-controlled, double-blind study design (TEV-50717 [low dose and high dose] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the…
- Trial name
- ARTISTS2 (NCT03571256)
- Testing
- TEV-50717
- Where
- 56 sites in United States, Argentina and 8 more
- Volunteers
- 158 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
Safety Study in subjects with Parkinson's Disease
- Trial name
- NCT00229736
- Testing
- AAV-hAADC-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple System Atrophy
GDNF Gene Therapy for Multiple System Atrophy
The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or…
- Trial name
- NCT04680065
- Testing
- AAV2-GDNF gene therapy
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Brain Neurotherapy Bio, Inc.
Huntington's Disease
A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease
The primary purpose of this study is to assess the effect of food upon the pharmacokinetics (PK) of SEN0014196 in subjects with Huntington disease (HD).
- Trial name
- NCT01485965
- Testing
- SEN0014196
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Siena Biotech S.p.A.
Tourette's Disorder
Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01416441
- Testing
- Aripiprazole
- Where
- 80 sites in United States, Bulgaria and 8 more
- Volunteers
- 170 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Progressive Supranuclear Palsy
Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
This study will evaluate the safety and tolerability (maximum tolerated dose (MTD) within the specified dosing range) of single intravenous (IV) infusion of C2N-8E12 in patients with progressive supranuclear palsy (PSP).
- Trial name
- NCT02494024
- Testing
- Single dose C2N-8E12
- Where
- 12 sites in United States
- Volunteers
- 32 people
- Sponsor
- C2N Diagnostics
Parkinson's Disease, HIV Infections
Using Heavy Water to Study Cell Dynamics in Parkinson's Disease
This pilot study will assess the feasibility of using heavy water as a safe 'tracer' for biomarker studies of diseases of the brain and spinal cord, that, together, are also called the central nervous system (CNS).
- Trial name
- NCT00990379
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Salena Killion
Parkinson's Disease
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study.
- Trial name
- 6002-010 (NCT00957203)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 308 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
Study to Assess the Safety and Effects of Autologous Adipose-Derived SVF Cells in Patients With Parkinson's Disease
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Parkinson's Disease and clinical outcomes.
- Trial name
- NCT01453803
- Testing
- Harvesting and Implantation of Adipose-Derived Stem Cells
- Where
- United States
- Sponsor
- Ageless Regenerative Institute
Parkinson Disease
WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects
The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics
- Trial name
- NCT04513340
- Testing
- WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS
- Where
- India
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Hong Kong WD Pharmaceutical Co., Limited
Parkinson's Disease (PD)
Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery
This clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have…
- Trial name
- NCT07550374
- Testing
- NouvNeu001 injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- iRegene Therapeutics Co., Ltd.
Essential Tremor, Parkinson's Disease
Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:
A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the…
- Conditions
- Essential Tremor, Parkinson's Disease, Movement Disorders, Neuropathic Pain
- Trial name
- NCT03100474
- Where
- 9 sites in United States, Canada and 2 more
- Volunteers
- 500 people
- Sponsor
- InSightec
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.